i2O Therapeutics develops GLP-1 combinations for cardio-renal-metabolic diseases. The company focuses on creating long-acting agonists for various targets including GLP-1r, Amylin, PYY, and Glucagon.

i2O Therapeutics

i2o Therapeutics is Boston-based company developing next generation biologic therapies

JDRF T1D Fund

Sanofi Ventures

Touchdown Ventures

Viva BioInnovator

i2o Therapeutics

i2o Therapeutics is hiring an Associate Principal/Senior Research Scientist! Come join our team and help us design formulations for novel biologics! #hiring

This Thursday, September 21, an important FDA Advisory Committee meeting granted by the Commissioner’s Office and FDA’s Chief Scientist will evaluate the data in support of ITCA 650 as a potential treatment for type 2 #diabetes. 
 
The Advisory Committee’s recommendation will be considered by The Office of the Commissioner, which will render a final decision regarding the pending New Drug Application (NDA) for ITCA 650 on behalf of the FDA in the coming months. 
 
Be sure to tune in to the public hearing this Thursday at 9am ET to see i2o present evidence supporting ITCA 650 as a safe and effective treatment for type 2 diabetes: https://bit.ly/3RsxrN4

In a recent Boston Business Journal article, Rowan Walrath spotlights #i2o and next steps for advancing our recently acquired pipeline assets and platform technology following the completion of our Series A financing and the appointment of Kurt Graves as Chairman, President and CEO.
 
Check out the article for more: bit.ly/3PhoCnG

#i2o CEO Kurt Graves sat down with Joseph Haas of Scrip to discuss his appointment as Chairman, President and CEO and highlight i2o’s recent progress, including the completion of our Series A financing and the acquisitions of proprietary pipeline assets and platform technology.
 
Check out the full article to learn the latest on i2o and how we aim to raise the standards of care in #diabetes, #obesity and related diseases with our next-generation biologics and peptides: https://lnkd.in/e8fHEyrZ

i2o Therapeutics is pleased to announce some exciting corporate updates, including the appointment of biotech industry leader Kurt Graves as Chairman, President and CEO, the successful completion of a Series A financing and the acquisitions of proprietary pipeline assets and platform technology.
 
Newly appointed CEO Kurt Graves said, “At i2o, our ultimate goal is to be an important part of the novel GLP-1 based combination products and innovative drug delivery solutions that are needed to raise the standards of care, address widespread unmet needs around poor control and poor adherence, and to help remove the barriers to access, affordability, and supply that are needed to help millions of patients.” 
 
Read the full press release to learn more about i2o’s recent progress and what’s next for the company: bit.ly/3PgOxfa

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 24, 2024 9:01 AM	d1fe95c4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
peers	general	Aug 24, 2024 9:01 AM	ab63bf69
news basic	general	Aug 24, 2024 9:01 AM	77bf1f60
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

I2OB

COM:I2OBIO

i2O Therapeutics